Study reveals artery stiffness from common cancer drug

NCT ID NCT04813913

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looked at how bevacizumab, a drug used to treat advanced colorectal cancer, affects the stiffness of arteries. Researchers measured artery stiffness in 13 patients before and after 4 months of treatment. The goal was to better understand the drug's cardiovascular side effects, like high blood pressure, and how they relate to cancer treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

bevacizumab (Avastin) combined with chemotherapy

What this could lead to

If successful, this could help doctors understand and manage the cardiovascular side effects of bevacizumab in colorectal cancer patients.

What could go wrong

This is a small, completed Phase 4 study with only 13 participants, so results may not apply broadly. It focuses on measuring artery stiffness, not on improving cancer outcomes.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ONCOLOGY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal cancer neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • CHU de ROUEN

    Rouen, France